FDA panel backs anemia drugs for kidney disease

October 18, 2010

(AP) -- Federal health advisers say patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

A panel of experts voted 15-1 to maintain the drugs' approval for patients with chronic who are not yet sick enough to receive dialysis. The FDA is not required to follow the group's advice, though it often does.

The panel is now scheduled to discuss altering recommended doses of the drugs to increase their safety.

The FDA is reviewing the three blood-boosting medications from Amgen Inc. after a study published last year that showed kidney disease patients taking them were twice as likely to experience compared with those taking a dummy treatment.


Related Stories

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.